Summary
Chairpersons: Prof. G. Minotti (ESC), Prof. J.-L. Zamorano (ESC), Dr C. Gottfridsson (AstraZeneca)
Objectives of the workshop
Cardio-oncology is the discipline that focuses on mechanisms and clinical manifestations of cardiovascular toxicity induced by cancer therapies.
Oncologists, haematologists, and radiation therapists are constantly faced with the risk of cardiovascular events in cancer patients. Old drugs are increasingly combined with or replaced by newer drugs, and hence cancer patients often present with a blend of toxicities. Furthermore, avalanches of new drugs are running in the pipeline of pharmaceutical companies, which anticipates the emergence of new clinical phenotypes of cardiovascular toxicity in the next few years. This calls for devising optimal but sustainable strategies of patient surveillance and prevention of cardiovascular events.
ESC is committed to promoting knowledge and awareness for all stakeholders in cardio-oncology (doctors, patients, caregivers, drug developers).
The aim of this workshop is to review main cardio-oncology issues from preclinical, clinical, and regulatory issues, thereby fostering cross-fertilization between academic and industrial parties.
New avenues to patient advocacy and research funding opportunities will also be explored
|
SESSION 1 |
CARDIO-ONCOLOGY: A REVIEW AND INTRODUCTION Moderated by J-L. Zamorano and Dr A. Chan (Pfizer) |
|
13:10 - 13:30 |
Cardiovascular Effects of Cancer Drugs: Mechanisms and Clinical Trajectories Prof. Giorgio Minotti, IT |
|
13:30 - 13:50 |
Radiation Therapy and Cardiovascular Disease Prof. J. H. Maduro, NL |
|
SESSION 2 |
CLINICAL MANAGEMENT OF CANCER PATIENTS Moderated by Prof. S. Achenbach and Prof. A. Goncalves (Philips) |
|
14:30 - 14:50 |
Cardiovascular Risk Stratification and Mitigation Prof. Thomas Suter, CH |
|
14:50 - 15:10 |
Early Diagnosis of Subclinical Cardiovascular Toxicity Dr Daniela Cardinale, IT |
|
15:10 - 15:30 |
Dr Juan Cardlos Plana Gomez, USA |
|
15:30 - 15:50 |
Hypertension, Atrial Fibrillation and Thrombosis Dr Riccardo Asteggiano, IT |
|
SESSION 3 |
PREVENTION AND TREATMENT Moderated by Prof. G. Minotti and Dr Soergel (Novartis) |
|
17:00 - 17:20 |
Current Recommendations: the ESC Consensus Document Prof. Jose Luis Zamorano, ES |
|
17:20 - 17:40 |
Dr Torbjørn Omland, NO |
|
17:40 - 18:00 |
Physical Exercise and Lifestyle: What Do We Know? Dr Jessica Scott, USA |
|
SESSION 4 |
CANCER DRUGS AND CV EVENTS IN SPECIAL POPULATIONS Moderated by Prof. T Suter and Dr Gottfridsson (AstraZeneca) |
| 08:45 - 09:05 |
Childhood Cancer Treatment and Lifelong Risk of Cardiovascular Events Dr E.A.M. Feijen, NL |
| 09:05 - 09:25 |
Cancer and Cardiovascular Risk in the Elderly Dr Teresa Lopez-Fernandez, ES |
| 09:25 - 09:45 |
New Immune Therapies and Cardiovascular Side Effects Dr Javid Moslehi, USA |
| SESSION 5 |
AN OUTLOOK Moderated by Prof. J.L. Zamorano and Dr S. Schroeder (Bayer) |
| 10:30 - 10:50 |
Prof. Giorgio Minotti, IT |
| 10:50 - 11:10 |
How the EU Framework Programme for Research Can Support Research on Interaction between Cancer and CVD Dr G. Owsianik, EU Commission |
| 11:10 - 11:30 |
How ECPC and ESC Could Join Forces as Advocates Ms Antonella Cardone, ECPC, European Cancer Patient Coalition |
| 11:30 - 11:50 |
Prof. Lina Badimon, ES |
Our mission: To reduce the burden of cardiovascular disease.